BRIEF-Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024

Reuters2023-10-18

Oct 18 (Reuters) - Baudax Bio Inc :

* BAUDAX BIO ANNOUNCES CORPORATE UPDATE

* BAUDAX BIO INC - PHASE 1/2A CLINICAL STUDY OF TI-168 IN HEMOPHILIA A WITH FVIII INHIBITORS PROJECTED TO BEGIN Q1 2024

* BAUDAX BIO INC - TO INITIATE TI-168 CLINICAL DEVELOPMENT FOLLOWING RECENT SHAREHOLDER APPROVAL OF CORPORATE ACTIONS RELATED TO TERAIMMUNE ACQUISITION

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2376414893?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-18 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2376414893","market":"us","top_or_hot":-1,"title":"BRIEF-Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024","media":"Reuters","content":"<html><body><p>Oct 18 (Reuters) - <a href=\"https://laohu8.com/S/BXRX\">Baudax Bio Inc</a>   :</p><p>   * BAUDAX BIO ANNOUNCES CORPORATE UPDATE</p><p>   * BAUDAX BIO INC - PHASE 1/2A CLINICAL STUDY OF TI-168 IN HEMOPHILIA A WITH FVIII INHIBITORS PROJECTED TO BEGIN Q1 2024</p><p>   * BAUDAX BIO INC - TO INITIATE TI-168 CLINICAL DEVELOPMENT FOLLOWING RECENT SHAREHOLDER APPROVAL OF CORPORATE ACTIONS RELATED TO TERAIMMUNE ACQUISITION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-18 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 18 (Reuters) - Baudax Bio Inc   :   * BAUDAX BIO ANNOUNCES CORPORATE UPDATE   * BAUDAX BIO INC - PHASE 1/2A CLINICAL STUDY OF TI-168 IN HEMOPHILIA A WITH FVIII INHIBITORS PROJECTED TO BEGIN Q1 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2376414893","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2376414893","pubTimestamp":1697631849,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 18  - Baudax Bio Inc   :   * BAUDAX BIO ANNOUNCES CORPORATE UPDATE   * BAUDAX BIO INC - PHASE 1/2A CLINICAL STUDY OF TI-168 IN HEMOPHILIA A WITH FVIII INHIBITORS PROJECTED TO BEGIN Q1 2024   * BAUDAX BIO INC - TO INITIATE TI-168 CLINICAL DEVELOPMENT FOLLOWING RECENT SHAREHOLDER APPROVAL OF CORPORATE ACTIONS RELATED TO TERAIMMUNE ACQUISITIONSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BXRX":"Baudax Bio, Inc."},"translate_title":"Baudax Bio称TI-168治疗血友病A的1/2期临床研究预计将于2024年Q1开始","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BXRX":0.9},"content_text":"Oct 18 (Reuters) - Baudax Bio Inc   :   * BAUDAX BIO ANNOUNCES CORPORATE UPDATE   * BAUDAX BIO INC - PHASE 1/2A CLINICAL STUDY OF TI-168 IN HEMOPHILIA A WITH FVIII INHIBITORS PROJECTED TO BEGIN Q1 2024   * BAUDAX BIO INC - TO INITIATE TI-168 CLINICAL DEVELOPMENT FOLLOWING RECENT SHAREHOLDER APPROVAL OF CORPORATE ACTIONS RELATED TO TERAIMMUNE ACQUISITIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2376414893"}